Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10223225 | 1.00 | RIPK1 (0.34) | RIPK1MEN1KMT2AHDAC6HDAC8 | |
| SCHEMBL10223178 | 1.00 | RIPK1 (0.34) | RIPK1MEN1KMT2AHDAC6HDAC8 | |
| SCHEMBL10223172 | 0.85 | PDK1 (0.36) | RIPK1MEN1KMT2AHDAC6HDAC8 | |
| SCHEMBL10223227 | 0.85 | LOXL2 (0.30) | RIPK1MEN1KMT2APDK2 | |
| SCHEMBL10223226 | 0.82 | TACR1 (0.33) | TACR1 | |
| SCHEMBL9963879 | 0.80 | ALDH1A1 (0.34) | RIPK1MEN1KMT2AHDAC6HDAC8 | |
| SCHEMBL24290292 | 0.78 | RIPK1 (0.33) | RIPK1MEN1KMT2AHDAC6HDAC8 | |
| SCHEMBL13698674 | 0.78 | CYP2D6 (0.35) | RIPK1MEN1KMT2AHDAC6HDAC8 | |
| SCHEMBL18701531 | 0.78 | CHRNB2 (0.42) | RIPK1MEN1KMT2A | |
| SCHEMBL17192616 | 0.78 | NR1H2 (0.42) | RIPK1MEN1KMT2AHDAC6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469662-B2 | Process for preparing optically active biophosphinylalkanes | BASF SE (DE) | 2016-10-18 | — | — | US | disclosed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | disclosed |
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-8026368-B2 | Hydrazide compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| EP-1913007-B1 | PROCESS FOR PREPARING OPTICALLY ACTIVE DIPHOSPHANES | BASF SE (DE) | 2011-06-22 | — | — | EP | disclosed |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080242893-A1 | Process for Preparing Optically Active Diphosphanes | BASF AKTIENGESELLSCHAFT (DE) | 2008-10-02 | — | — | US | disclosed |
| EP-1913007-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE DIPHOSPHANES | BASF SE (DE) | 2008-04-23 | — | — | EP | disclosed |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-13 | — | — | US | disclosed |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-13 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| WO-2007012655-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE DIPHOSPHANES | BASF SE (DE) | 2007-02-01 | — | — | WO | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | RIPK1 1154/4885MEN1 3655/4885KMT2A 3391/4885 |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, KDR | RIPK1 2702/4885MEN1 4271/4885KMT2A 2894/4885 |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | RIPK1 528/4885MEN1 1165/4885KMT2A 811/4885 |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | RIPK1 614/4885MEN1 3231/4885KMT2A 2353/4885 |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, THPO, PTAFR | RIPK1 3473/4885MEN1 427/4885KMT2A 3245/4885 |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | RIPK1 614/4885MEN1 3231/4885KMT2A 2353/4885 |
| US-20080242893-A1 | Process for Preparing Optically Active Diphosphanes | PHOSPHO1, DCTPP1, DCPS | RIPK1 3760/4885MEN1 1123/4885KMT2A 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.